- Home
- OKYO vs LVTX Comparison
OKYO vs LVTX Comparison
Compare OKYO & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- LVTX
- Stock Information
- Founded
- OKYO 2007
- LVTX 2016
- Country
- OKYO United Kingdom
- LVTX Netherlands
- Employees
- OKYO N/A
- LVTX N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- OKYO Health Care
- LVTX Health Care
- Exchange
- OKYO Nasdaq
- LVTX Nasdaq
- Market Cap
- OKYO 37.0M
- LVTX 34.2M
- IPO Year
- OKYO 2022
- LVTX 2021
- Fundamental
- Price
- OKYO $1.19
- LVTX $1.25
- Analyst Decision
- OKYO Strong Buy
- LVTX Hold
- Analyst Count
- OKYO 1
- LVTX 3
- Target Price
- OKYO $7.00
- LVTX $3.17
- AVG Volume (30 Days)
- OKYO 143.7K
- LVTX 67.1K
- Earning Date
- OKYO 04-08-2025
- LVTX 03-28-2025
- Dividend Yield
- OKYO N/A
- LVTX N/A
- EPS Growth
- OKYO N/A
- LVTX N/A
- EPS
- OKYO N/A
- LVTX N/A
- Revenue
- OKYO N/A
- LVTX $11,982,000.00
- Revenue This Year
- OKYO N/A
- LVTX N/A
- Revenue Next Year
- OKYO N/A
- LVTX N/A
- P/E Ratio
- OKYO N/A
- LVTX N/A
- Revenue Growth
- OKYO N/A
- LVTX 77.01
- 52 Week Low
- OKYO $0.81
- LVTX $0.85
- 52 Week High
- OKYO $1.74
- LVTX $3.57
- Technical
- Relative Strength Index (RSI)
- OKYO 45.06
- LVTX 47.85
- Support Level
- OKYO $1.31
- LVTX $1.20
- Resistance Level
- OKYO $1.48
- LVTX $1.36
- Average True Range (ATR)
- OKYO 0.11
- LVTX 0.08
- MACD
- OKYO -0.03
- LVTX -0.02
- Stochastic Oscillator
- OKYO 17.07
- LVTX 23.53
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.